Division of Cardiovascular Medicine and Cardiovascular Institute, Stanford University, Stanford, California.
Michael E. DeBakey Veterans Affairs Medical Center, Section of Cardiovascular Research, Department of Medicine, Baylor College of Medicine, Houston, Texas.
JAMA Cardiol. 2019 Mar 1;4(3):206-213. doi: 10.1001/jamacardio.2018.4936.
Statins decrease mortality in those with atherosclerotic cardiovascular disease (ASCVD), but statin adherence remains suboptimal.
To determine the association between statin adherence and mortality in patients with ASCVD who have stable statin prescriptions.
DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort analysis included patients who were between ages 21 and 85 years and had 1 or more International Classification of Diseases, Ninth Revision, Clinical Modification codes for ASCVD on 2 or more dates in the previous 2 years without intensity changes to their statin prescription who were treated within the Veterans Affairs Health System between January 1, 2013, and April 2014.
Statin adherence was defined by the medication possession ratio (MPR). Adherence levels were categorized as an MPR of less than 50%, 50% to 69%, 70% to 89%, and 90% or greater. For dichotomous analyses, adherence was defined as an MPR of 80% or greater.
The primary outcome was death of all causes adjusted for demographic and clinical characteristics, as well as adherence to other cardiac medications.
Of 347 104 eligible adults with ASCVD who had stable statin prescriptions, 5472 (1.6%) were women, 284 150 (81.9%) were white, 36 208 (10.4%) were African American, 16 323 (4.7%) were Hispanic, 4093 (1.2%) were Pacific Islander, 1293 (0.4%) were Native American, 1145 (0.3%) were Asian, and 1794 (0.5%) were other races. Patients taking moderate-intensity statin therapy were more adherent than patients taking high-intensity statin therapy (odds ratio [OR], 1.18; 95% CI, 1.16-1.20). Women were less adherent (OR, 0.89; 95% CI, 0.84-0.94), as were minority groups. Younger and older patients were less likely to be adherent compared with adults aged 65 to 74 years. During a mean (SD) of 2.9 (0.8) years of follow-up, there were 85 930 deaths (24.8%). Compared with the most adherent patients (MPR ≥ 90%), patients with an MPR of less than 50% had a hazard ratio (HR; adjusted for clinical characteristics and adherence to other cardiac medications) of 1.30 (95% CI, 1.27-1.34), those with an MPR of 50% to 69% had an HR of 1.21 (95% CI, 1.18-1.24), and those with an MPR of 70% to 89% had an HR of 1.08 (95% CI, 1.06-1.09).
Using a national sample of Veterans Affairs patients with ASCVD, we found that a low adherence to statin therapy was associated with a greater risk of dying. Women, minorities, younger adults, and older adults were less likely to adhere to statins. Our findings underscore the importance of finding methods to improve adherence.
他汀类药物可降低动脉粥样硬化性心血管疾病(ASCVD)患者的死亡率,但他汀类药物的依从性仍然不理想。
确定在稳定的他汀类药物处方的 ASCVD 患者中,他汀类药物的依从性与死亡率之间的关系。
设计、设置和参与者:这项回顾性队列分析纳入了年龄在 21 岁至 85 岁之间的患者,在过去 2 年内至少有 2 次 ASCVD 的国际疾病分类第 9 版临床修正代码,且他汀类药物处方强度无变化,在退伍军人事务部医疗系统内接受治疗,时间为 2013 年 1 月 1 日至 2014 年 4 月。
他汀类药物的依从性通过药物利用率(MPR)来定义。依从性水平分为 MPR 小于 50%、50%至 69%、70%至 89%和 90%或更高。对于二项分析,依从性定义为 MPR 大于 80%。
主要结局是调整人口统计学和临床特征以及其他心脏药物的依从性后,所有原因导致的死亡。
在 347104 名符合条件的 ASCVD 稳定服用他汀类药物的成年人中,5472 名(1.6%)为女性,284150 名(81.9%)为白人,36208 名(10.4%)为非裔美国人,16323 名(4.7%)为西班牙裔,4093 名(1.2%)为太平洋岛民,1293 名(0.4%)为美洲原住民,1145 名(0.3%)为亚裔,1794 名(0.5%)为其他种族。服用中等强度他汀类药物治疗的患者比服用高强度他汀类药物治疗的患者更依从(比值比[OR],1.18;95%置信区间[CI],1.16-1.20)。女性患者(OR,0.89;95%CI,0.84-0.94)和少数族裔患者的依从性较低。与 65 至 74 岁的成年人相比,年轻和年老的患者不太可能遵守医嘱。在平均(标准差)2.9(0.8)年的随访期间,有 85930 人死亡(24.8%)。与依从性最高的患者(MPR≥90%)相比,MPR 小于 50%的患者的风险比(HR;调整临床特征和其他心脏药物的依从性)为 1.30(95%CI,1.27-1.34),MPR 为 50%至 69%的患者 HR 为 1.21(95%CI,1.18-1.24),MPR 为 70%至 89%的患者 HR 为 1.08(95%CI,1.06-1.09)。
使用退伍军人事务部 ASCVD 患者的全国样本,我们发现他汀类药物治疗依从性低与死亡风险增加相关。女性、少数族裔、年轻成年人和老年成年人不太可能坚持服用他汀类药物。我们的研究结果强调了寻找提高依从性方法的重要性。